Apr 20, 2023 / 07:00PM GMT
Gil Blum - Needham & Company - Analyst
Good afternoon, everyone, and thank you for joining me at the fourth day of the Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham and I cover the immuno-oncology and gene therapy subsectors. It is my pleasure to have with me today Nurix's CEO, Dr. Arthur Sands.
As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask a Question box below the video feed window.
Questions and Answers:
Gil Blum - Needham & Company - AnalystSo Arthur, maybe a good place to start just as an overview, provide some introductory remarks on Nurix. And not everyone is familiar with protein degradation, but what is it and how is Nurix doing it different?
Arthur Sands - Nurix Therapeutics, Inc. - President & CEO
Certainly. And first off, thanks, Gil, and thanks to the Needham team for hosting us. So targeted protein degradation, I can dive in and say one of
Trustpilot
